Athersys

Athersys company information, Employees & Contact Information

Explore related pages

Related company profiles:

Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. We are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.

Company Details

Employees
33
Founded
-
Address
3201 Carnegie Ave, Cleveland,oh 44115,united States
Phone
(216)431-9900
Email
in****@****sys.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Cleveland, OH
Looking for a particular Athersys employee's phone or email?

Athersys Questions

News

Athersys files for bankruptcy, sells assets to Healios in wake of stroke cell therapy’s struggles - Fierce Biotech

Athersys files for bankruptcy, sells assets to Healios in wake of stroke cell therapy’s struggles Fierce Biotech

Athersys Announces Expansion of Collaboration With Healios - GlobeNewswire

Athersys Announces Expansion of Collaboration With Healios GlobeNewswire

Healios Acquires Bankrupt Athersys, Expands Cell Therapy R&D Programs - Citeline News & Insights

Healios Acquires Bankrupt Athersys, Expands Cell Therapy R&D Programs Citeline News & Insights

Therapies Targeting Stroke Recovery - American Heart Association Journals

Therapies Targeting Stroke Recovery American Heart Association Journals

Athersys Adds to Surge of Biotechs Filing for Bankruptcy, Sells to Healios - BioSpace

Athersys Adds to Surge of Biotechs Filing for Bankruptcy, Sells to Healios BioSpace

Athersys bankruptcy filing could lead to sale of most assets to development partner - Cleveland.com

Athersys bankruptcy filing could lead to sale of most assets to development partner Cleveland.com

Athersys and UH Cleveland trial stem cell therapy for Covid-19 - Clinical Trials Arena

Athersys and UH Cleveland trial stem cell therapy for Covid-19 Clinical Trials Arena

Athersys granted clinical Type B meeting with US FDA to discuss MASTERS-2 trial - NeuroNews International

Athersys granted clinical Type B meeting with US FDA to discuss MASTERS-2 trial NeuroNews International

Bankruptcy of once-promising Athersys winding down with assets sale - The Business Journals

Bankruptcy of once-promising Athersys winding down with assets sale The Business Journals

Athersys' struggles mount with employee terminations, Nasdaq delisting upcoming - Crain's Cleveland Business

Athersys' struggles mount with employee terminations, Nasdaq delisting upcoming Crain's Cleveland Business

Identification of a human NF-κB-activating protein, TAB3 - PNAS

Identification of a human NF-κB-activating protein, TAB3 PNAS

Athersys inches closer to bankruptcy as stroke cell therapy fails interim analysis - Fierce Biotech

Athersys inches closer to bankruptcy as stroke cell therapy fails interim analysis Fierce Biotech

Athersys shares suspended by Nasdaq, now trading over the counter - Cleveland.com

Athersys shares suspended by Nasdaq, now trading over the counter Cleveland.com

Athersys and one of its directors battle over corporate governance - The Business Journals

Athersys and one of its directors battle over corporate governance The Business Journals

Athersys announces ‘disappointing’ results from MASTERS-2 interim analysis - NeuroNews International

Athersys announces ‘disappointing’ results from MASTERS-2 interim analysis NeuroNews International

Not an 'excellent outcome' for Athersys stock as stem cell therapy misses endpoint in Japanese trial - Fierce Biotech

Not an 'excellent outcome' for Athersys stock as stem cell therapy misses endpoint in Japanese trial Fierce Biotech

Financially strapped Athersys raises $10.4M - Cleveland.com

Financially strapped Athersys raises $10.4M Cleveland.com

Gil van Bokkelen's vision, energy made Athersys an industry leader, chairman says - The Business Journals

Gil van Bokkelen's vision, energy made Athersys an industry leader, chairman says The Business Journals

Athersys director and large shareholder takes corporate governance battle to court - The Business Journals

Athersys director and large shareholder takes corporate governance battle to court The Business Journals

Athersys shares delisted by Nasdaq Stock Market - The Business Journals

Athersys shares delisted by Nasdaq Stock Market The Business Journals

Athersys warns of bankruptcy risk as it pauses enrollment in key clinical trial - Crain's Cleveland Business

Athersys warns of bankruptcy risk as it pauses enrollment in key clinical trial Crain's Cleveland Business

Bankrupt Athersys Inc. sells its assets for $2.25 million - Crain's Cleveland Business

Bankrupt Athersys Inc. sells its assets for $2.25 million Crain's Cleveland Business

Athersys’ MultiStem® Therapy for COVID-19 Designated “Highly Relevant” by BARDA - BioInformant

Athersys’ MultiStem® Therapy for COVID-19 Designated “Highly Relevant” by BARDA BioInformant

Biotech company expects to expand in Stow, add 400 jobs - Akron Beacon Journal

Biotech company expects to expand in Stow, add 400 jobs Akron Beacon Journal

Athersys files for bankruptcy, plans to sell assets - Crain's Cleveland Business

Athersys files for bankruptcy, plans to sell assets Crain's Cleveland Business

Gil Van Bokkelen is out as chairman and CEO of Athersys Inc. - Crain's Cleveland Business

Gil Van Bokkelen is out as chairman and CEO of Athersys Inc. Crain's Cleveland Business

Athersys, Inc. announced that it has received $15 million in funding - MarketScreener

Athersys, Inc. announced that it has received $15 million in funding MarketScreener

Athersys Inc. adds Maia Hansen as senior vice president, operations and supply chain - Crain's Cleveland Business

Athersys Inc. adds Maia Hansen as senior vice president, operations and supply chain Crain's Cleveland Business

Researchers From Case Western Reserve and Athersys Publish Landmark Study Showing Regenerative Benefit of MultiStem Therapy After Spinal Cord Injury - NBC News

Researchers From Case Western Reserve and Athersys Publish Landmark Study Showing Regenerative Benefit of MultiStem Therapy After Spinal Cord Injury NBC News

Here's Why Athersys Stock Is Soaring Today - The Motley Fool

Here's Why Athersys Stock Is Soaring Today The Motley Fool

Athersys (NASDAQ: ATHX) stock up 40% after bankruptcy warning - yes, after - Dhaka Tribune

Athersys (NASDAQ: ATHX) stock up 40% after bankruptcy warning - yes, after Dhaka Tribune

Top Athersys Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant